Please type a plus sign (+) inside this box → ⊞

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	6

Complete if Known	
Application Number	10/022,276
Filing Date	14-Dec-2001
First Named Inventor	Gosselin, *et al.*
Group Art Unit	1623
Examiner Name	L. Eric Crane
Attorney Docket Number	06171.105005 (NOV 1000 CON)

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. [1]	U.S. Patent Document Number	Kind Code [2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	4,916,122	A	Chu et al.	04-10-1990	
	AB	4,957,924	A	Beauchamp	09-18-1990	
	AC	5,190,926	A	Chu et al.	03-02-1993	
	AD	5,194,654	A	Hostetler et al.	03-16-1993	
	AE	5,223,263	A	Hostetler et al.	06-29-1993	
	AF	5,256,641	A	Yatvin et al.	10-01-1993	
	AG	5,411,947	A	Hostetler et al.	05-02-1995	
	AH	5,463,092	A	Hostetler et al.	10-31-1995	
	AI	5,539,116	A	Liotta et al.	07-23-1996	
	AJ	5,543,389	A	Yatvin et al.	08-06-1996	
	AK	5,543,390	A	Yatvin et al.	08-06-1996	
	AL	5,543,391	A	Yatvin et al.	08-06-1996	
	AM	5,554,728	A	Basava et al.	09-10-1996	
~~**~~		~~5,559,101~~		~~Weis et al.~~	09-24-1996	
	AO	5,565,438	A	Chu et al.	10-15-1996	
	AP	5,567,688	A	Chu et al.	10-22-1996	
	AQ	5,587,362	A	Chu et al.	12-24-1996	
~~**~~		~~5,939,402~~		~~Weis et al.~~	08-17-1999	
~~**~~		~~6,025,335~~		~~Weis et al.~~	02-15-2000	
	AR	6,194,391	B1	Schinazi et al.	02-27-2001	
	AS	6,245,749	B1	Schinazi et al.	06-12-2001	

** Duplicate: see PTO-892 for cite.

Examiner Signature	L. E. Crane	Date Considered	04/09/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	2	of	6

Complete if Known	
Application Number	10/022,276
Filing Date	14-Dec-2001
First Named Inventor	Gosselin, *et al.*
Group Art Unit	1623
Examiner Name	L. Eric Crane
Attorney Docket Number	06171.105005 (NOV 1000 CON)

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. [1]	Foreign Patent Document Office [3]	Number	Kind Code [2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [6]
LEC	AT	WO	89/02733	A1	University of California	04-06-1989		
LEC	AU[	WO	90/00555	A1	Vical, Inc.	01-25-1990		
LEC	AV	WO	91/16920	A1	Vical, Inc.	11-14-1991		
LEC	AW	WO	91/18914	A1	Vical, Inc.	12-12-1991		
LEC	AX	WO	91/19721	A1	Glazier	12-26-1991		
LEC	AY	WO	92/08727	A1	]CNDR (Italy)	05/29/92		
LEC	AZ	WO	92/15308	A1	Wellcome	09-17-1992		
LEC	BA	WO	92/18517	A1	Yale et al.	10-29-1992		
LEC	BB	WO	93/00910	A1	Vical, Inc.	01-21-1993		
**		~~WO~~	~~94/20523~~		~~Burroughs Wel~~come	09-15-1994		
LEC	BC	WO	94/26273	A1	Hostetler	11-24-1994		
LEC	BD	WO	95/07086	A1	Emory University	03/16/95		
LEC	BE	WO	96/13512	A2	Genencor	05-09-1996		
LEC	BF	WO	96/15132	A1	University of California	05-23-1996		
LEC	BG	WO	96/40164	A1	Emory University	12-19-1996		
LEC	BH	EP	0 350 287	A2	Vical, Inc.	02-10-1990		
LEC	BI	EP	0 494 119	A1	BioChem Pharma	07-08-1992		
LEC	BJ	JP	06-293645	A2	Saneyoshi et al.	10-21-1994	Abstract only	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T [6]
LEC	BK	BLOCH, et al. "The Role Of The 5'-Hydroxyl Group Of Adenosine In Determining Substrate Specificity For Adenosine Deaminase." *J. Med. Chem.* 10(5), 908-12 (September 1967).	

** Duplicate: See PTO-892 for cite.

Examiner Signature	L. E. Crane	Date Considered	04/09/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

COPY FOR [1] File [ ] Applicant

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	3	of	6

Complete if Known	
Application Number	10/022,276
Filing Date	14-Dec-2001
First Named Inventor	Gosselin, *et al.*
Group Art Unit	1623
Examiner Name	L. Eric Crane
Attorney Docket Number	06171.105005 (NOV 1000 CON)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
~~**~~		~~BRYANT et al., "Antiviral L-Nucleosides Specific~~ for Hepatitis B Virus Infection," *Antimicrobial Agents and Chemotherapy*, 45(1), 229-235 (January 2001).	
	BL	CHANG, et al., "Deoxycytidine Deaminase-resistant Stereoisomer is the Active Form of (-)-2',3'-thiacytidine in the Inhibition of Hepatitis B Virus Replication," *Journal of Biological Chemistry*, Volume 267(20), 13938-13942 (July 15, 1992).	
	BM!	DAVISSON, et al., "Synthesis of Nucleotide 5'-Diphosphates from 5'-O-Tosyl Nucleosides," *J. Org. Chem.*, 52(9), 1794-1801 (1987)	
	BN	DU et al, Synthesis, "Anti-Human Immunodeficiency Virus and Anti-Hepatitis B Virus Activities of Novel Oxaselenolane Nucleosides," *J. of Med. Chem.*, (40)19, 2991-2993 (September 12, 1997).	
	BO	FURMAN, et al., "The Anti-Hepatitis B Virus Activities, Cytotoxicities, and Anabolic Profiles of the (-) and (+) Enantiomers of cis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-oxathiolane-5-yl]-Cytosine" *Antimicrobial Agents and Chemotherapy*, 36(12) 2686-2692 (December 1992).	
	BP	GOSSELIN, G. et al. "Synthesis and Antiviral Evaluation of β-L-Xylofuranosyl Nucleosides of the Five Naturally Occuring Nucleic Acid Bases", *Journal of Heterocyclic Chemistry*, 1993, 30 (Oct.-Nov.), 1229-1233.	
	BQ!	HOARD, et al., "Conversion of Mono- and Oligodeoxyribonucleotides to 5'-Triphosphates," *J. Am. Chem. Soc.*, 87(8), 1785-1788 (1965).	
	BR!	HOLY. "Nucleic Acid Components and Their Analogs. CLIII. Preparation of 2'-deoxy-L-Ribonucleosides of the Pyrimidine Series," *Collect. Czech. Chem. Commun.* (1972), 37(12), 4072-87.	
	BS	HOSTETLER, K.Y., et al. "Greatly Enhanced Inhibition Of Human Immunodeficiency Virus Type 1 Replication In CEM And HT4-6C Cells By 3'-Deoxythymidine Diphosphate Dimyristoylglycerol, A Lipid Prodrug Of 3'-Deoxythymidine." (September 1992) *Antimicrob Agents Chemother.* 36:2025-2029.	
	BT	HOSTETLER, K.Y., et al. "Synthesis And Antiretroviral Activity Of Phospholipid Analogs Of Azidothymidine And Other Antiviral Nucleosides." (April 15, 1990) *J. Biol Chem.* 265(11):6112-7.	

** Duplicate: See PTO-892 for cite.
! Month of publication could not be determined from the copy provided.

Examiner Signature	L. E. Crane	Date Considered	04/09/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

COPY FOR [X] FIle [ ] APplicant

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 6

Complete if Known	
Application Number	10/022,276
Filing Date	14-Dec-2001
First Named Inventor	Gosselin, *et al.*
Group Art Unit	1623
Examiner Name	L. Eric Crane
Attorney Docket Number	06171.105005 (NOV 1000 CON)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. [1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
ME	BU	IMAI et al., "Studies on Phosphorylation. IV. Selective Phosphorylation of the Primary Hydroxyl Group in Nucleosides." *J. Org. Chem.*, 34(6), 1547-1550 (June 1969).	
ME	BV	JONES, R. et al., "Mini Review: Nucleotide prodrugs," *Antiviral Research*, 27, 1-17 (1995).	
ME	BW!	KORBA et al., "A cell culture assay for compounds which inhibit hepatitis B virus replication," *Antiviral Res.*, 15:217 (1991).	
ME	BX	KUCERA, L.S., et al., "Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation." *AIDS Res Hum Retroviruses*. 6:491-501 (May 1990).	
ME	BY	LIN et al., "Synthesis of Several Pyrimidine L-Nucleoside Analogues as Potential Antiviral Agents," *Tetrahedron :* , Vol. 51(4), 1055,1068 (1995).	
**		~~LIN et al., "Design and Synthesis of 2',3'-Dideoxy-~~2', 3'-didyhydro-β-L-cytidine (β-L-Fd4C), Two Exceptionally Potent Inhibitors of Human HBV and Potent Inhibitors of HIV *In Vitro*," *J. Med. Chem.*, 39(9), 1757-1759 (April 26,1996).	
ME	BZ	MAGA et al., "Lack of stereospecificity of suid pseudorabies virus thymidine kinase," *Biochem. J.* , 294(2), 381-385 (September 1, 1993).	
**		~~MANSOUR et al., "Stereochemical Aspects of the Anti-~~HCMV Activity of Cytidine Nucleoside Analogues," *Antiviral Chemistry & Chemotherapy*, 6(3), 138-142 (1995).	
ME	CA	NAKAYAMA, C., et al., "Synthetic Nucleosides and Nucleotides. XX. Synthesis of Various 1-β-Xylofuranosyl-5-Alkyluracils and Related Nucleosides." *Nucleosides, Nucleotides*, 1, 139-146 (1982)	
ME	CB	NORBECK, *Tetrahedron Letters*, 30 (46), 6246 (1989)	
ME	CC	ROBINS, M. J. et al. "Purine nucleosides. XXIX. The synthesis of 2'-deoxy-L-adenosine and 2'-deoxy-L-guanosine and their alpha anomers." *J. Org. Chem.* March 1970, 35, 636-639.	
ME	CD	ROBINS, M.J., et al., "Nucleic Acid Related Compounds. 42. A General Procedure for the Efficient Deoxygenation of Secondary Alcohols. Regiospecific and Stereoselective Conversion of Ribonucleosides to 2'-Deoxynucleosides." *J. Am. Chem. Soc.* 105, 4059-4065 (1983). (June 15, 1983)	

! Month of publication could not be determined from the copy provided.

** Duplicate: See PTO-892 for cite.

Examiner Signature	L. E. Crane	Date Considered	04/09/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

COPY FOR [X] File [ ] Applicant

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 6

Complete if Known	
Application Number	10/022,276
Filing Date	14-Dec-2001
First Named Inventor	Gosselin, *et al.*
Group Art Unit	1623
Examiner Name	L. Eric Crane
Attorney Docket Number	06171.105005 (NOV 1000 CON)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
~~LEC~~		~~ROBINS, "Selective Deoxygenation and Modification~~ at C2' of Nucleosides," *Nucleic Acids Research Symposium Series*, Vol. 11, Pages 1-4, Kyoto, Japan, November 24-26, 1982, A.E. Pritchard (ed.), IRL Press, Ltd., Oxford, England, 1982;	
LEC	CE !	SANEYOSHI, M., et al., "Synthetic Nucleosides and Nucleotides. XIII. Stannic Chloride Catalyzed Ribosylation of Several 6-Substituted Purines." *Chem. Pharm. Bull.*, 27, 2518-2521 (1979).;	
LEC	CF	SCHINAZI, et al., "Selective Inhibition of Human Immunodeficiency Viruses by Racemates and Enantiomers of cis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-Oxathiolane-5-yl] Cytosine," *Antimicrobial Agents and Chemotherapy*, 36(11), 2423-2431 (1992). (November, 1992)	
LEC	CG	SCHINAZI, et al., "Effect of Combinations of Acylovir with Vidarabine or its 'Monophosphate on Herpes Simplex Viruses in Cell Culture and in Mice," *Antimicrobial Agents and Chemotherapy*, 22(3), 499, (1982). (July, 1982)	
LEC	CH !	SHUTO, S., et al. "A facile one-step synthesis of 5'-phosphatidylnucleosides by an enzymatic two-phase reaction." *Tetrahedron Letters*. 28. 199-202 (1987).	
~~LEC~~		~~SPADARI et al., "L-Thymidine is Phosphorylated by~~ Herpes Simplex Type 1 Thymidine Kinase and Inhibits Viral Growth," *J. Med. Chem.* (1992), 35(22), 4214-4220.	
LEC	CI	TYRSTED et al. "Inhibition of the synthesis of 5-phosphoribosyl-1-pyrophosphate by 3'-deoxy-adenosine and structurally related nucleoside analogs." *Biochim. Biophys. Acta.* (February 26, 1968), 155(2), 619-22.	
LEC	CJ	VERRI et al. "Lack of enantiospecificity of human 2'-deoxycytidine kinase: relevance for the activation of beta-L-deoxycytidine analogs as antineoplastic and antiviral agents." *Molecular Pharmacology*. (January 1997), 51(1), 132-138.	
~~LEC~~		~~VERRI et al., "Relaxed Enantioselectivity of Human Mitochon~~drial Thymidine Kinase and Chemotherapeutic Uses of L-Nucleoside Analogues," *Biochem. J.* (1997), 328(1), 317-320 (November 15, 1997).	

** Duplicate; see PTO-892.

! Month of publication data is unavailable from the copy supplied.

Examiner Signature	L. E. Crane	Date Considered	04/09/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

COPY FOR [X] File [ ] APplicant

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	6	of	6

Complete if Known	
Application Number	10/022,276
Filing Date	14-Dec-2001
First Named Inventor	Gosselin, *et al.*
Group Art Unit	1623
Examiner Name	L. Eric Crane
Attorney Docket Number	06171.105005 (NOV 1000 CON)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. !	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[6]
~~**~~		~~von JANTA-LIPINSKI et al., "Newly Synthesized L-~~ Enantiomers of 3'-Fluoro-Modified β-2'-Deoxyribonucleoside 5'-Triphosphates Inhibit Hepatitis B DNA Polymerase but not the Five Cellular DNA Polymerases α, β, γ, δ, and ε Nor HIV-1 Reverse Transcriptase," *J. Medicinal Chemistry*, 41(12), 2040-2046 (June 4, 1996).	
CK	CK !	ZEDECK et al. "Pseudomonas testosteroni," *Mol. Phys.* (1967), 3(4), 386-95.	
CL	CL !	ZHANG, W., et al. "Removal of Silyl Protecting Groups from Hydroxyl Functions with Ammonium Fluoride in Methanol." *Tetrahedron Letter.*, 33, 1177-1180 (192).	

** Duplicate: see PTO-892.

! Month of publication data could not be determined from the copy supplied.

Examiner Signature	L. E. Crane	Date Considered	04/09/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

COPY FOR [X] File [ ] Applicant